日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)

一项多中心回顾性研究(GUIDANCE002)表明,新辅助经动脉化疗栓塞联合酪氨酸激酶和免疫检查点抑制剂可提高可切除肝细胞癌患者的生存率。

Yang, Da-Long; Qin, Chuang; Peng, Ning; Liu, Shao-Ping; Yu, Ya-Qun; Nong, Jun-Liang; Zeng, Fan-Jian; Su, Ze; Yang, Yong-Yu; Yang, Fu-Quan; Li, Mian-Jing; Wu, Ming-Song; Wang, Xue-Yao; Liang, Yong-Rong; Li, Fu-Xin; Chen, Shu-Chang; Lai, Yong-Cheng; Pang, Qing-Qing; Zhong, Teng-Meng; Yan, Yi-He; Zhang, Ying-Yu; Ye, Lin; Dong, Xiao-Feng; Li, Wen-Feng; Liu, Jie; Yao, Hong-Bing; Wu, Pei-Sheng; Mao, Xian-Shuang; Ou, Jun-Jie; Chen, Yao-Zhi; Wang, Guo-Dong; Chen, Kang; Deng, Zhu-Jian; Su, Jia-Yong; Qiu, Guo-Gao; Liu, Zhi-Dong; Wang, Jin-Min; Zhang, Yi; Liang, Xiu-Mei; Xiang, Bang-De; Ma, Liang; Zhong, Jian-Hong

Phase II Trial of Hypofractionated Radiotherapy and Immunochemotherapy in Primary Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results and Insights from Digital Spatial Profiling.

原发性难治性弥漫性大B细胞淋巴瘤的低分割放射治疗和免疫化疗的II期试验:数字空间分析的初步结果和见解

Yang Yong, Yu Jing, Hu Xiao-Mei, Chen Si-Lin, Zhao Rui-Zhi, Huang Cheng, Guo Jiang-Rui, Tang Tian-Lan, Chen Cheng, Lin Yu-Ping, Wang Ying, Liu Tian-Xiu, Zheng Hao, Liao Si-Qin, Chen Jin-Hua, Fu Hai-Ying, Liu Ting-Bo

A novel risk stratification system for primary small-cell carcinoma of the esophagus: indication for prognostication and staging

食管原发性小细胞癌的新型风险分层系统:预后和分期的适应症

Yang, Yong; Yu, Jing; Chen, Silin; Wang, Xiaomin; Wu, Furong; Huang, Cheng; Lin, Yuping; Tang, Tianlan; Gao, Tiantian; Zhang, Zewei; Zhang, Yiping; Wang, Liyan; Chen, Junqiang; Zhang, Zhenyang; Wang, Weijie; Lin, Jiangbo; Wang, Ying; Xu, Yuanji; Zhao, Lei

Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study

不可切除肝细胞癌转化治疗后完全或部分缓解行肝切除术的生存获益(GUIDANCE003):一项多中心研究

Yang, Da-Long; Peng, Ning; Nong, Jun-Liang; Chen, Kang; Su, Ze; Yu, Ya-Qun; Ye, Lin; Zeng, Fan-Jian; Liu, Shao-Ping; Yan, Yi-He; Wang, Xue-Yao; Yao, Hong-Bing; Yang, Fu-Quan; Li, Wen-Feng; Qin, Chuang; Wu, Ming-Song; Yang, Yong-Yu; Dong, Xiao-Feng; Li, Mian-Jing; Liu, Jie; Liang, Yong-Rong; Wu, Pei-Sheng; Zhong, Teng-Meng; Lai, Yong-Cheng; Chen, Yao-Zhi; Pang, Qing-Qing; Wang, Guo-Dong; Li, Fu-Xin; Mao, Xian-Shuang; Chen, Shu-Chang; Ou, Jun-Jie; Huo, Rong-Rui; Liang, Xiu-Mei; Xiang, Bang-De; Ma, Liang; Zhong, Jian-Hong

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)

PD-1抑制剂联合疗法治疗不可切除肝细胞癌后临床完全缓解的预后价值(GUIDANCE006)

Ma, Liang; Yang, Da-Long; Zhong, Teng-Meng; Pang, Qing-Qing; Luo, Min; Li, Wen-Feng; Yan, Yi-He; Chen, Kang; Wang, Guo-Dong; Yang, Fu-Quan; Lai, Yong-Cheng; Wu, Ming-Song; Dong, Xiao-Feng; Yang, Yong-Yu; Peng, Ning; Nong, Jun-Liang; Su, Ze; Yu, Ya-Qun; Ye, Lin; Zeng, Fan-Jian; Liu, Shao-Ping; Wang, Xue-Yao; Yao, Hong-Bing; Qin, Chuang; Li, Mian-Jing; Liu, Jie; Liang, Yong-Rong; Wu, Pei-Sheng; Li, Fu-Xin; Chen, Shu-Chang; Lu, Si-Cong; Li, Zhi-Cheng; Liu, Zhen; Guo, Ping-Ping; Pan, Li-Xin; Zhong, Jian-Hong

New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024

2022年至2024年间,治疗代谢功能障碍相关性脂肪性肝炎(MASH)的新型药物治疗候选药物取得了新的进展

Wong, Shu Wei; Yang, Yong-Yu; Chen, Hui; Xie, Li; Shen, Xi-Zhong; Zhang, Ning-Ping; Wu, Jian

Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)

放射学和病理学完全缓解对不可切除肝细胞癌患者进行免疫转化治疗的预后价值(GUIDANCE004)

Yang, Da-Long; Yan, Yi-He; Lai, Yong-Cheng; Wu, Ming-Song; Dong, Xiao-Feng; Chen, Yao-Zhi; Li, Wen-Feng; Yang, Fu-Quan; Yang, Yong-Yu; Zhong, Teng-Meng; Wang, Guo-Dong; Pang, Qing-Qing; Chen, Kang; Peng, Ning; Nong, Jun-Liang; Su, Ze; Yu, Ya-Qun; Ye, Lin; Zeng, Fan-Jian; Liu, Shao-Ping; Wang, Xue-Yao; Yao, Hong-Bing; Qin, Chuang; Zhang, Ying-Yu; Liu, Jie; Li, Mian-Jing; Liang, Yong-Rong; Wu, Pei-Sheng; Li, Fu-Xin; Mao, Xian-Shuang; Chen, Shu-Chang; Ou, Jun-Jie; Luo, Min; Lu, Si-Cong; Li, Zhi-Cheng; Huang, Shen; Su, Jia-Yong; Chen, Huan; Zhang, Yi-Ge; Liang, Xiu-Mei; Ma, Yi-Li; Ma, Liang; Zhong, Jian-Hong

Gut microbiota-derived metabolites modulate Treg/Th17 balance: novel therapeutic targets in autoimmune diseases

肠道菌群代谢产物调节 Treg/Th17 平衡:自身免疫性疾病的新型治疗靶点

Li, Guolin; Xiong, Yu; Li, Zhimin; Yu, Qin; Li, Shiran; Xie, Jingxian; Zeng, Siyu; Yu, Dongke; Yang, Yong; Yu, Jiangping

Shenfushu granules attenuate diabetic kidney disease by inhibiting PIK3R1/protein kinase B/heparanase-mediated endothelial-mesenchymal transition

参福舒颗粒通过抑制PIK3R1/蛋白激酶B/肝素酶介导的内皮-间质转化来减轻糖尿病肾病。

Yang, Xi-Ding; Ma, Si-Jia; Xiang, Da-Xiong; Yang, Yong-Yu

Gut microbiota and metabolomic profiles of tacrolimus-induced DILI in renal transplant recipients: a population-based case control study

肾移植受者他克莫司诱导的药物性肝损伤的肠道菌群和代谢组学特征:一项基于人群的病例对照研究

Li, Guolin; Hou, Yifu; Zhang, Lijuan; Chen, Lu; Yang, Yong; Yu, Dongke